Researchers have been able to mobilize the brain’s native stem cells to replenish a type of neuron lost in Huntington’s disease.
In the study, which appears today in the journal Cell Stem Cell, the scientists were able to both trigger the production of new neurons in mice with the disease and show that the new cells successfully integrated into the brain’s existing neural networks, dramatically extending the survival of the treated mice.
“This study demonstrates the feasibility of a completely new concept to treat Huntington’s disease, by recruiting the brain’s endogenous neural stem cells to regenerate cells lost to the disease,” said University of Rochester Medical Center (URMC) neurologist Steve Goldman, M.D., Ph.D., co-director of Rochester’s Center for Translational Neuromedicine.
Huntington’s disease is an inherited neurodegenerative disease characterized by the loss of a specific cell type called the medium spiny neuron, a cell that is critical to motor control. The disease, which affects some 30,000 people in the U.S., results in involuntary movements, problems with coordination, and, ultimately, in cognitive decline and depression. There is currently no way to slow or modify this fatal disease.
For Goldman, the idea behind his strategy to treat the disease emerged from his decades-long study of neural plasticity in canaries. Songbirds like canaries have intrigued biologists because of their ability — unique in the animal kingdom — to lay down new neurons in the adult brain. This process, called adult neurogenesis, was first discovered by Goldman and Fernando Nottebohm of the Rockefeller University in the early 1980s, when the two realized that when learning new songs new neurons were added to regions of the bird’s brain responsible for vocal control.
“Our work with canaries essentially provided us with the information we needed to understand how to add new neurons to adult brain tissue,” said Goldman. “Once we mastered how this happened in birds, we set about how to replicate the process in the adult mammalian brain.”
Humans already possess the ability to create new neurons. Goldman’s lab demonstrated in the 1990s that a font of neuronal precursor cells exist in the lining of the ventricles, structures found in the core of the human brain. In early development, these cells are actively producing neurons. However, shortly after birth the neural stem cells stop generating neurons and instead produce glia, a family of support cells that pervade the central nervous system. Some parts of the human brain continue to produce neurons into adulthood, the most prominent example is the hippocampus where memories are formed and stored. But in the striatum, the region of the brain that is devastated by Huntington’s disease, this capability is “switched off” in adulthood.
Goldman and his team spent the past decade attempting to unravel the precise chemical signaling responsible for instructing neural stem cells when to create neurons and when to create glia cells. One of the most critical clues came directly from the earlier research with canaries. In the part of the bird’s brain were new songs are acquired and neurons added, the scientists observed the regulated expression of a protein called brain derived neurotrophic factor, or BDNF. When the production of this protein is triggered, the local neural stem cells are instructed to produce neurons.
At the same time, the scientists also realized that they had to simultaneously suppress the bias of these stem cells to produce glia. They found that when BDNF was combined with another molecule called noggin — a protein that inhibits the chemical pathway that dictates the creation of glial cells — they could successfully switch the stem cell’s molecular machinery over to the production of neurons.
The next challenge was how to deliver these two proteins — BDNF and noggin — precisely and in a sustained fashion to the area of the brain involved in Huntington’s disease. To do so, they partnered with scientists at the University of Iowa to modify a viral gene therapeutic, called an adeno-associated virus, to deliver the necessary molecular instructions to the neural stem cells.
The virus infected the target cells in the brains of mice with Huntington’s disease and triggered the sustained over-expression of both BDNF and noggin. This, in turn, activated the neighboring neural stem cells which began to produce medium spiny motor neurons. The new neurons were continuously generated and migrated to the striatum, the region of the brain impacted by Huntington’s disease, where they then integrated into the existing neuronal networks.
The researchers were able to significantly extend the survival of the treated mice, in some cases doubling their life expectancy.
The Latest Bing News on:
Huntington’s Disease
- A year on, Teva CEO Richard Francis celebrates progress in 'Pivot to Growth' planon May 8, 2024 at 12:02 pm
In about a year after launching a revamp strategy under CEO Richard Francis, Teva has managed to return its generics business to growth, secure approvals for a pair of high-profile biosimilars | While ...
- Join the 3rd Annual Golf for a Cure for Huntington’s Diseaseon May 8, 2024 at 10:21 am
The Massachusetts and Rhode Island Chapters of the Huntington’s Disease Society of America want you to help find a cure by joining this year’s golf for a cure ...
- Teva Pharm Q1 profit misses estimates, revenue riseaon May 8, 2024 at 4:56 am
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to ...
- Research suggests tear fluid testing as promising method for Huntington’s Disease monitoringon May 7, 2024 at 2:15 pm
Huntington's disease (HD) is an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age.
- Huntington’s Disease Treatment Market Value: Understanding Pricing and Valuation Trendson May 6, 2024 at 11:24 pm
The global Huntington?s disease treatment market revenue was around US$ 316.5 million in 2021 and is estimated to reach US$ 708.2 million by 2031, growing at a compound annual growth rate (CAGR) of ...
- Team Hope brings awareness to Lake Comoon May 5, 2024 at 9:44 am
Hundreds of racers and community members gathered in the Bar Anticipation parking lot early Saturday morning as they awaited the start of the 7th ...
- Team Hope Walk raises awareness for Huntington’s Diseaseon May 5, 2024 at 1:54 am
Saturday for the Team Hope Statewide Walk. The walk was to raise money for Huntington’s Disease. Huntington’s disease is a rare, neurodegenerative disease that causes nerve cells in the brain to ...
- Leprosy drug may be effective in Huntington's disease, study suggestson May 3, 2024 at 6:16 am
A preclinical study from Karolinska Institutet offers hope for treating severe neurodegenerative diseases with an existing drug. The study suggests that the leprosy drug clofazimine may be effective ...
- US FDA approves Neurocrine Biosciences' movement disorder drugon May 2, 2024 at 8:21 am
April 30 (Reuters) - (This April 30 story has been corrected to say it was Neurocrine's movement disorder drug, not Huntington's disease drug, in the headline and to remove the reference to chorea ...
- Neurocrine Biosciences' Huntington's disease drug gets FDA approvalon April 30, 2024 at 10:15 pm
Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability.
The Latest Google Headlines on:
Huntington’s Disease
[google_news title=”” keyword=”Huntington’s Disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Huntington’s disease treatment
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adultson May 9, 2024 at 5:30 am
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ...
- FDA Clears Ingrezza Sprinkle for Bipolar-Linked Tardive Dyskinesiaon May 8, 2024 at 1:58 pm
Ingrezza Sprinkle (valbenazine) offers an alternative for those who have trouble swallowing pills or prefer a different method of taking medication.
- A year on, Teva CEO Richard Francis celebrates progress in 'Pivot to Growth' planon May 8, 2024 at 12:02 pm
In about a year after launching a revamp strategy under CEO Richard Francis, Teva has managed to return its generics business to growth, secure approvals for a pair of high-profile biosimilars | While ...
- Teva Pharmaceutical’s stock climbs as schizophrenia treatment shows promiseon May 8, 2024 at 6:15 am
Teva Pharmaceutical Industries stock jumped more than 6% early Wednesday after the company reported first-quarter sales that topped estimates and released positive late-stage trial data on a ...
- REFILE-UPDATE 1-Teva Pharm Q1 profit misses estimates, revenue riseson May 8, 2024 at 4:56 am
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to ...
- Research suggests tear fluid testing as promising method for Huntington’s Disease monitoringon May 7, 2024 at 2:15 pm
Huntington's disease (HD) is an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age.
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progresson May 7, 2024 at 12:05 am
We expect to complete this evaluation mid-2024.” Recent Updates Advancing AMT-130 for the treatment of Huntington’s disease The Company is on track to initiate interactions with the U.S. Food and Drug ...
- Huntington’s Disease Treatment Market Value: Understanding Pricing and Valuation Trendson May 6, 2024 at 11:24 pm
The global Huntington?s disease treatment market revenue was around US$ 316.5 million in 2021 and is estimated to reach US$ 708.2 million by 2031, growing at a compound annual growth rate (CAGR) of ...
- A sprinkling of good news for the treatment of HD choreaon May 3, 2024 at 1:18 pm
A new form of the chorea drug valbenazine (INGREZZA) has been approved by the United States Food and Drug Administration (FDA) for those who have difficulty swallowing pills.
- Leprosy drug may be effective in Huntington's disease, study suggestson May 3, 2024 at 6:16 am
A preclinical study from Karolinska Institutet offers hope for treating severe neurodegenerative diseases with an existing drug. The study suggests that the leprosy drug clofazimine may be effective ...
The Latest Google Headlines on:
Huntington’s disease treatment
[google_news title=”” keyword=”Huntington’s disease treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]